Form 4: Xencor Director Ellen Feigal Reports Stock and Option Transactions

Director Ellen Feigal reported the acquisition of common stock and stock options in Xencor, Inc.

Summary

• On June 13, 2024, Ellen Feigal, a director of Xencor, Inc. [XNCR], reported transactions involving the company's securities.
• Feigal acquired 5,986 shares of common stock at $0 and disposed of 10,993 shares.
• Following these transactions, she beneficially owns 10,993 shares of common stock.
• Additionally, Feigal acquired options to purchase 11,971 shares of common stock at an exercise price of $21.31, which will vest in equal monthly installments over one year beginning on July 13, 2024.
• These options expire on June 12, 2034.

Sentiment

Score: 5

Explanation: The sentiment is neutral. It's a standard disclosure of stock transactions by a company director. The acquisition of options could be seen as slightly positive, while the disposal of shares is slightly negative, balancing out overall.

Positives

• The acquisition of stock options by a director could be seen as a positive signal, indicating confidence in the company's future performance.

Negatives

• The disposal of 10,993 shares of common stock by a director could be interpreted negatively by some investors.

Risks

• The vesting schedule of the stock options and restricted stock units could influence the director's decisions regarding the company's stock.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedule of the stock options and restricted stock units suggests a continued relationship between the director and the company.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotechnology industry, used to align the interests of management with those of shareholders.
• Vesting schedules, like the one described in the filing, are standard practice to incentivize long-term commitment.
• Comparing the size of the option grant and the exercise price to those of peer companies (e.g., Amgen, Regeneron, Biogen) would provide further context on the competitiveness of Xencor's executive compensation.

Stakeholder Impact

• The transactions may influence investor sentiment regarding Xencor's stock.
• Employees may view the director's stock activity as a reflection of the company's prospects.

Key Dates